The anglerfish and uremic
The anglerfish and uremic
复制标题
DOI：
10.1096/fj.11-0602ufm
复制
发表时间：
2011-06-01
期刊：
影响因子：
4.8
通讯作者：
Lowenstein, Jerome
中科院分区：
文献类型：
--
作者：
Lowenstein, Jerome
1960年，贝尔丁·斯克里布纳引入血液透析作为慢性肾功能衰竭的治疗方法。现在，50年后的今天，很明显，虽然尿毒症的一些特征(酸中毒、高钾血症、神经异常和尿毒症相关的骨病)可以通过血液透析得到纠正或改善，但慢性肾功能衰竭的一些重要特征(即心血管疾病的发病率大大增加以及肾脏疤痕和功能丧失的不可避免的进展)似乎不会受到血液透析的影响。也许是时候重新审视我们在这半个世纪里对尿毒症的了解了。在肾功能很少或没有肾功能的患者中维持生命的能力是一项非常伟大的成就，无论是技术上的还是(国会承认慢性肾功能衰竭患者的治疗是一种只有在美国政府的财政支持下才能实现的情况)、社会(1)。这项立法导致了这个国家生物技术的爆炸性增长。新的和更好的透析器和透析膜的开发在孔隙率和生物活性方面具有不同的质量，成为一个主要的行业，与之平行的是一种新的医生类别的出现和迅速激增-透析医生加入了
In 1960, Belding Scribner introduced hemodialysis as a treatment for chronic renal failure. Now, 50 years later, it has become quite clear that while some features of uremia (acidosis, hyperkalemia, neurologic abnormalities, and uremia-related bone disease) are corrected or improved by hemodialysis, several important features of chronic renal failure (namely the greatly increased incidence of cardiovascular disease and the inexorable progression of renal scarring and loss of function) do not seem to be affected by hemodialysis. Perhaps the time has come to reexamine what we have learned about uremia during this half century. The ability to sustain life in patients with little or no renal function was a very great achievement, both technical and (with the recognition by Congress that the treatment of patients with chronic renal failure was a condition that could only be achieved with the financial support of the US government), social (1). This legislation resulted in an explosion of biotechnology in this country. The development of new and better dialyzers and dialysis membranes with different qualities in regard to porosity and biologic reactivity became a major industry and was paralleled by the appearance and rapid proliferation of a new category of physicians—dialysis physicians joined the small ranks of